Syndax Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 343.49, 486.23, 672.81, 904.13, 1098.12 ], "ebit_estimate": [ -122.98, -14.52, 109.85, 295.67, 435.56 ], "ebitda_estimate": [ -126.4, -27.06, 106.88, null, null ], "net_income_estimate": [ -152.85, -66.26, 71.71, 263.58, 327.22 ], "per_share_eps_estimate": [ -1.67, -0.59, 0.68, 2.49, 3.1 ], "eps_nri_estimate": [ -1.75, -0.72, 0.61, 2.49, 3.1 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ -0.31, 0.04, 0.72, null, null ], "pretax_income_estimate": [ -161.74, -42.58, 63.77, 240.49, 393.75 ], "operating_cash_flow_per_share_estimate": [ -1.3, 0, 0.63, null, null ], "roa_estimate": [ -24.1, -2.8, 10.6, null, null ], "roe_estimate": [ -409.71, 85.3, 182.09, null, null ], "gross_margin_estimate": [ 89.9, 89.9, 90.24, 86.83, 87.1 ], "operating_cash_flow_estimate": [ -114.73, 0, 55.6, null, null ], "pettm_estimate": [ 0, 0, 34.53, 9.49, 7.63 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "55.79", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 55.79, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -1.83, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 79.33, 92.37, 109.14, null, null, null, null ], "ebit_estimate": [ -35.63, -28.34, -22.72, null, null, null, null ], "ebitda_estimate": [ -35.77, -29.04, -21.86, null, null, null, null ], "net_income_estimate": [ -38.59, -32.08, -26.95, null, null, null, null ], "per_share_eps_estimate": [ -0.49, -0.39, -0.35, null, null, null, null ], "eps_nri_estimate": [ -0.48, -0.4, -0.35, -0.09, -0.24, -0.1, -0.16 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -39.92, -34.69, -32.56, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ -0.24, 0.38, 1.34, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -252.29, -190.51, -660.42, null, null, null, null ], "gross_margin_estimate": [ 88.48, 88.45, 88.27, null, null, null, null ], "operating_cash_flow_estimate": [ -21.18, 33.54, 117.82, null, null, null, null ], "pettm_estimate": [ null, null, null, null, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "55.79", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 55.79, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -1.83, "future_operating_cash_flow_per_share_estimate_growth": null }